Michael J. Rudy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael J. Rudy has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Kenneth L. Tyler
Department of Neurology University of Colorado School of Medicine Aurora CO
4 shared publications - Joshua Frost
Department of Neurology, University of Colorado School of Medicine, Aurora, USA
3 shared publications - Penny Clarke
Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA
3 shared publications - Margot Mayer-Pröschel
Department of Biomedical Genetics, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
2 shared publications Penny Clarke
Department of Neurology, University of Colorado, Aurora, Colorado, USA
2 shared publicationsAlison M. Hixon
Medical Scientist Training Program, University of Colorado, Aurora, Colorado, USA
1 shared publication
Latest Publications
- Open Access
- 9 April 2025
- Published by American Society for Microbiology in mBio
- Vol. 16 (4) , e0390624
EV68-228-N monoclonal antibody treatment halts progression of paralysis in a mouse model of EV-D68 induced acute flaccid myelitis
In 2014, 2016, and 2018, infection with enterovirus D68 (EV-D68) was associated with outbreaks of a poliomyelitis-like paralytic syndrome, called acute flaccid myelitis (AFM). While only a small fraction of patients infected with EV-D68 developed AFM, this subgroup of patients does not typically seek treatment until after the onset of neurological symptoms. There are currently no approved human monoclonal antibody therapies or vaccines available for EV-D68. Here, we show that a monoclonal antibody, EV68-228-N, can quickly stop the progression of paralysis in a mouse model of AFM, even when treatment is initiated after the onset of paralysis. We found that EV68-228-N effectively halted the progression of paralysis when tested against both 2014 and 2016 EV-D68 isolates in an immunocompetent mouse model of AFM. All animal experiments were conducted in a blinded fashion. The IC 50 of EV68-228-N against 2014 and 2016 EV-D68 isolates was confirmed in vitro to be less than 330 ng/mL, and EV68-228-N was found to be equally effective at neutralizing 2018 and 2022 viral isolates without any evidence of emerging resistance. We further show that, following infection with EV-D68, mice treated with EV68-228-N have more surviving motor neurons in the spinal cord’s lumbar enlargement than control treated animals. Taken together, this work suggests that EV68-228-N treatment has the potential to halt the progression of paralysis in AFM patients who present at the clinic with neurologic symptoms and that EV68-228-N will retain neutralization potential against emerging EV-D68 isolates. IMPORTANCE: Enterovirus D-68 (EV-D68) associated acute flaccid myelitis (AFM) is an emergent poliomyelitis-like illness occurring predominantly in children. There are currently no proven effective therapies. We describe the use of a human monoclonal antibody (EV68-228-N) in a murine model of EV-D68 AFM in which therapy prevents progression of paralysis even when treatment is instituted after onset of weakness. Clinical Trials: This study is registered with ClinicalTrials.gov as NCT06444048 .
- 9 April 2025
- Published by American Society for Microbiology in mBio
- Vol. 16 (4) , e0390624
Open AccessEV68-228-N monoclonal antibody treatment halts progression of paralysis in a mouse model of EV-D68 induced acute flaccid myelitis
In 2014, 2016, and 2018, infection with enterovirus D68 (EV-D68) was associated with outbreaks of a poliomyelitis-like paralytic syndrome, called acute flaccid myelitis (AFM). While only a small fraction of patients infected with EV-D68 developed AFM, this subgroup of patients does not typically seek treatment until after the onset of neurological symptoms. There are currently no approved human monoclonal antibody therapies or vaccines available for EV-D68. Here, we show that a monoclonal antibody, EV68-228-N, can quickly stop the progression of paralysis in a mouse model of AFM, even when treatment is initiated after the onset of paralysis. We found that EV68-228-N effectively halted the progression of paralysis when tested against both 2014 and 2016 EV-D68 isolates in an immunocompetent mouse model of AFM. All animal experiments were conducted in a blinded fashion. The IC 50 of EV68-228-N against 2014 and 2016 EV-D68 isolates was confirmed in vitro to be less than 330 ng/mL, and EV68-228-N was found to be equally effective at neutralizing 2018 and 2022 viral isolates without any evidence of emerging resistance. We further show that, following infection with EV-D68, mice treated with EV68-228-N have more surviving motor neurons in the spinal cord’s lumbar enlargement than control treated animals. Taken together, this work suggests that EV68-228-N treatment has the potential to halt the progression of paralysis in AFM patients who present at the clinic with neurologic symptoms and that EV68-228-N will retain neutralization potential against emerging EV-D68 isolates. IMPORTANCE: Enterovirus D-68 (EV-D68) associated acute flaccid myelitis (AFM) is an emergent poliomyelitis-like illness occurring predominantly in children. There are currently no proven effective therapies. We describe the use of a human monoclonal antibody (EV68-228-N) in a murine model of EV-D68 AFM in which therapy prevents progression of paralysis even when treatment is instituted after onset of weakness. Clinical Trials: This study is registered with ClinicalTrials.gov as NCT06444048 .
- 23 July 2024
- Published by American Society for Microbiology in Journal of Virology
- Vol. 98 (7) , e0039724
VP1 is the primary determinant of neuropathogenesis in a mouse model of enterovirus D68 acute flaccid myelitis
Enterovirus D68 (EV-D68) is an emerging pathogen that can cause severe respiratory and neurologic disease [acute flaccid myelitis (AFM)]. Intramuscular (IM) injection of neonatal Swiss Webster (SW) mice with US/IL/14-18952 (IL52), a clinical isolate from the 2014 EV-D68 epidemic, results in many of the pathogenic features of human AFM, including viral infection of the spinal cord, death of motor neurons, and resultant progressive paralysis. In distinction, CA/14-4231 (CA4231), another clinical isolate from the 2014 EV-D68 outbreak, does not cause paralysis in mice, does not grow in the spinal cord, and does not cause motor neuron loss following IM injection. A panel of chimeric viruses containing sequences from IL52 and CA4231 was used to demonstrate that VP1 is the main determinant of EV-D68 neurovirulence following IM injection of neonatal SW mice. VP1 contains four amino acid differences between IL52 and CA4231. Mutations resulting in substituting these four amino acids (CA4231 residues into the IL52 polyprotein) completely abolished neurovirulence. Conversely, mutations resulting in substituting VP1 IL52 amino acid residues into the CA4231 polyprotein created a virus that induced paralysis to the same degree as IL52. Neurovirulence following infection of neonatal SW mice with parental and chimeric viruses was associated with viral growth in the spinal cord. IMPORTANCE: Emerging viruses allow us to investigate mutations leading to increased disease severity. Enterovirus D68 (EV-D68), once the cause of rare cases of respiratory illness, recently acquired the ability to cause severe respiratory and neurologic disease. Chimeric viruses were used to demonstrate that viral structural protein VP1 determines growth in the spinal cord, motor neuron loss, and paralysis following intramuscular (IM) injection of neonatal Swiss Webster (SW) mice with EV-D68. These results have relevance for predicting the clinical outcome of future EV-D68 epidemics as well as targeting retrograde transport as a potential strategy for treating virus-induced neurologic disease.
- 23 July 2024
- Published by American Society for Microbiology in Journal of Virology
- Vol. 98 (7) , e0039724
VP1 is the primary determinant of neuropathogenesis in a mouse model of enterovirus D68 acute flaccid myelitis
Enterovirus D68 (EV-D68) is an emerging pathogen that can cause severe respiratory and neurologic disease [acute flaccid myelitis (AFM)]. Intramuscular (IM) injection of neonatal Swiss Webster (SW) mice with US/IL/14-18952 (IL52), a clinical isolate from the 2014 EV-D68 epidemic, results in many of the pathogenic features of human AFM, including viral infection of the spinal cord, death of motor neurons, and resultant progressive paralysis. In distinction, CA/14-4231 (CA4231), another clinical isolate from the 2014 EV-D68 outbreak, does not cause paralysis in mice, does not grow in the spinal cord, and does not cause motor neuron loss following IM injection. A panel of chimeric viruses containing sequences from IL52 and CA4231 was used to demonstrate that VP1 is the main determinant of EV-D68 neurovirulence following IM injection of neonatal SW mice. VP1 contains four amino acid differences between IL52 and CA4231. Mutations resulting in substituting these four amino acids (CA4231 residues into the IL52 polyprotein) completely abolished neurovirulence. Conversely, mutations resulting in substituting VP1 IL52 amino acid residues into the CA4231 polyprotein created a virus that induced paralysis to the same degree as IL52. Neurovirulence following infection of neonatal SW mice with parental and chimeric viruses was associated with viral growth in the spinal cord. IMPORTANCE: Emerging viruses allow us to investigate mutations leading to increased disease severity. Enterovirus D68 (EV-D68), once the cause of rare cases of respiratory illness, recently acquired the ability to cause severe respiratory and neurologic disease. Chimeric viruses were used to demonstrate that viral structural protein VP1 determines growth in the spinal cord, motor neuron loss, and paralysis following intramuscular (IM) injection of neonatal Swiss Webster (SW) mice with EV-D68. These results have relevance for predicting the clinical outcome of future EV-D68 epidemics as well as targeting retrograde transport as a potential strategy for treating virus-induced neurologic disease.
- Open Access
- 3 March 2023
- Published by The Company of Biologists in Development
- Vol. 150 (20)
Gestational iron deficiency affects the ratio between interneuron subtypes in the postnatal cerebral cortex in mice
Gestational iron deficiency (gID) is highly prevalent and associated with an increased risk of intellectual and developmental disabilities in affected individuals that are often defined by a disrupted balance of excitation and inhibition (E/I) in the brain. Using a nutritional mouse model of gID, we previously demonstrated a shift in the E/I balance towards increased inhibition in the brains of gID offspring that was refractory to postnatal iron supplementation. We thus tested whether gID affects embryonic progenitor cells that are fated towards inhibitory interneurons. We quantified relevant cell populations during embryonic inhibitory neuron specification and found an increase in the proliferation of Nkx2.1+ interneuron progenitors in the embryonic medial ganglionic eminence at E14 that was associated with increased Shh signaling in gID animals at E12. When we quantified the number of mature inhibitory interneurons that are known to originate from the MGE, we found a persistent disruption of differentiated interneuron subtypes in early adulthood. Our data identify a cellular target that links gID with a disruption of cortical interneurons which play a major role in the establishment of the E/I balance.
- 3 March 2023
- Published by The Company of Biologists in Development
- Vol. 150 (20)
Open AccessGestational iron deficiency affects the ratio between interneuron subtypes in the postnatal cerebral cortex in mice
Gestational iron deficiency (gID) is highly prevalent and associated with an increased risk of intellectual and developmental disabilities in affected individuals that are often defined by a disrupted balance of excitation and inhibition (E/I) in the brain. Using a nutritional mouse model of gID, we previously demonstrated a shift in the E/I balance towards increased inhibition in the brains of gID offspring that was refractory to postnatal iron supplementation. We thus tested whether gID affects embryonic progenitor cells that are fated towards inhibitory interneurons. We quantified relevant cell populations during embryonic inhibitory neuron specification and found an increase in the proliferation of Nkx2.1+ interneuron progenitors in the embryonic medial ganglionic eminence at E14 that was associated with increased Shh signaling in gID animals at E12. When we quantified the number of mature inhibitory interneurons that are known to originate from the MGE, we found a persistent disruption of differentiated interneuron subtypes in early adulthood. Our data identify a cellular target that links gID with a disruption of cortical interneurons which play a major role in the establishment of the E/I balance.
- 16 August 2022
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 66 (8) , e0022722
Neutralizing Antibody Given after Paralysis Onset Reduces the Severity of Paralysis Compared to Nonspecific Antibody-Treated Controls in a Mouse Model of EV-D68-Associated Acute Flaccid Myelitis
Enterovirus D68 (EV-D68) can cause mild to severe respiratory illness and is associated with a poliomyelitis-like paralytic syndrome called acute flaccid myelitis (AFM). Most cases of EV-D68-associated AFM occur in young children who are brought to the clinic after the onset of neurologic symptoms.
- 16 August 2022
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 66 (8) , e0022722
Neutralizing Antibody Given after Paralysis Onset Reduces the Severity of Paralysis Compared to Nonspecific Antibody-Treated Controls in a Mouse Model of EV-D68-Associated Acute Flaccid Myelitis
Enterovirus D68 (EV-D68) can cause mild to severe respiratory illness and is associated with a poliomyelitis-like paralytic syndrome called acute flaccid myelitis (AFM). Most cases of EV-D68-associated AFM occur in young children who are brought to the clinic after the onset of neurologic symptoms.
- Open Access
- 23 February 2022
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10 (1) , e0245221
Density Analysis of Enterovirus D68 Shows Viral Particles Can Associate with Exosomes
Despite the strong causal link between enterovirus D68 (EV-D68) and acute flaccid myelitis (AFM), it remains unclear how EV-D68 gains entry into the central nervous system and what receptors enable it to infect motor neurons. We show that EV-D68 particles can adhere to exosomes, placing EV-D68 among a handful of other picornaviruses which are known to interact with extracellular vesicles.
- 23 February 2022
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10 (1) , e0245221
Open AccessDensity Analysis of Enterovirus D68 Shows Viral Particles Can Associate with Exosomes
Despite the strong causal link between enterovirus D68 (EV-D68) and acute flaccid myelitis (AFM), it remains unclear how EV-D68 gains entry into the central nervous system and what receptors enable it to infect motor neurons. We show that EV-D68 particles can adhere to exosomes, placing EV-D68 among a handful of other picornaviruses which are known to interact with extracellular vesicles.
- Open Access
Understanding Enterovirus D68-Induced Neurologic Disease: A Basic Science Review
In 2014, the United States (US) experienced an unprecedented epidemic of enterovirus D68 (EV-D68)-induced respiratory disease that was temporally associated with the emergence of acute flaccid myelitis (AFM), a paralytic disease occurring predominantly in children, that has a striking resemblance to poliomyelitis. Although a definitive causal link between EV-D68 infection and AFM has not been unequivocally established, rapidly accumulating clinical, immunological, and epidemiological evidence points to EV-D68 as the major causative agent of recent seasonal childhood AFM outbreaks in the US. This review summarizes evidence, gained from in vivo and in vitro models of EV-D68-induced disease, which demonstrates that contemporary EV-D68 strains isolated during and since the 2014 outbreak differ from historical EV-D68 in several factors influencing neurovirulence, including their genomic sequence, their receptor utilization, their ability to infect neurons, and their neuropathogenicity in mice. These findings provide biological plausibility that EV-D68 is a causal agent of AFM and provide important experimental models for studies of pathogenesis and treatment that are likely to be difficult or impossible in humans.
Open AccessUnderstanding Enterovirus D68-Induced Neurologic Disease: A Basic Science Review
In 2014, the United States (US) experienced an unprecedented epidemic of enterovirus D68 (EV-D68)-induced respiratory disease that was temporally associated with the emergence of acute flaccid myelitis (AFM), a paralytic disease occurring predominantly in children, that has a striking resemblance to poliomyelitis. Although a definitive causal link between EV-D68 infection and AFM has not been unequivocally established, rapidly accumulating clinical, immunological, and epidemiological evidence points to EV-D68 as the major causative agent of recent seasonal childhood AFM outbreaks in the US. This review summarizes evidence, gained from in vivo and in vitro models of EV-D68-induced disease, which demonstrates that contemporary EV-D68 strains isolated during and since the 2014 outbreak differ from historical EV-D68 in several factors influencing neurovirulence, including their genomic sequence, their receptor utilization, their ability to infect neurons, and their neuropathogenicity in mice. These findings provide biological plausibility that EV-D68 is a causal agent of AFM and provide important experimental models for studies of pathogenesis and treatment that are likely to be difficult or impossible in humans.
- Open Access
- 1 November 2017
- Published by Taylor & Francis in ASN Neuro
- Vol. 9 (6)
Iron Deficiency Affects Seizure Susceptibility in a Time- and Sex-Specific Manner
Iron deficiency (ID) affects more than three billion people worldwide making it the most common micronutrient deficiency. ID is most prevalent during gestation and early life, which is of particular concern since its impact on the developing central nervous system is associated with an increased risk of a wide range of different psychiatric disorders later in life. The cause for this association is not known, but many of these same disorders are also associated with an imbalance between excitation and inhibition (E/I) within the brain. Based on this shared impairment, we asked whether ID could contribute to such an imbalance. Disruptions in the E/I balance can be uncovered by the brain’s response to seizure inducing insults. We therefore tested the seizure threshold under different nutritional models of ID. We found that mice which were postnatally exposed to ID (and were acutely ID) had a decreased seizure threshold and increased susceptibility to certain seizure types. In contrast, mice that were exposed to ID only during gestation had an increased seizure threshold and low seizure incidence. We suggest that exposure to ID during gestation might alter the cellular components that contribute to the establishment of a proper E/I balance later in life. In addition, our data highlight the importance of considering the window of vulnerability since gestational ID and postnatal ID have significantly different consequences on seizure probability.
- 1 November 2017
- Published by Taylor & Francis in ASN Neuro
- Vol. 9 (6)
Open AccessIron Deficiency Affects Seizure Susceptibility in a Time- and Sex-Specific Manner
Iron deficiency (ID) affects more than three billion people worldwide making it the most common micronutrient deficiency. ID is most prevalent during gestation and early life, which is of particular concern since its impact on the developing central nervous system is associated with an increased risk of a wide range of different psychiatric disorders later in life. The cause for this association is not known, but many of these same disorders are also associated with an imbalance between excitation and inhibition (E/I) within the brain. Based on this shared impairment, we asked whether ID could contribute to such an imbalance. Disruptions in the E/I balance can be uncovered by the brain’s response to seizure inducing insults. We therefore tested the seizure threshold under different nutritional models of ID. We found that mice which were postnatally exposed to ID (and were acutely ID) had a decreased seizure threshold and increased susceptibility to certain seizure types. In contrast, mice that were exposed to ID only during gestation had an increased seizure threshold and low seizure incidence. We suggest that exposure to ID during gestation might alter the cellular components that contribute to the establishment of a proper E/I balance later in life. In addition, our data highlight the importance of considering the window of vulnerability since gestational ID and postnatal ID have significantly different consequences on seizure probability.